StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines bRUKINSA — China Net Product Revenue ($M) ($M)

Form 10-Q / 10-K MD&A

Latest, FY2025
344
Period ended Dec 31, 2025
Change on a year earlier
+33.3%
258 in FY2024
History
5 years
Since FY2021
Sources
5
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBRUKINSA — China Net Product Revenue ($M) ($M)Year on yearSource
FY2025Dec 31, 2025344+33.3%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 2024258+33.2%Form 10-K (filed 2025-02-27) ↗
FY2023Dec 31, 2023194+28.9%Form 10-K (filed 2024-02-26) ↗
FY2022Dec 31, 2022150+48.5%Form 10-K (filed 2023-02-27) ↗
FY2021Dec 31, 2021101–Form 10-K (filed 2022-02-28) ↗

Breakdown

What makes up brukinsa — china net product revenue ($m)

Cite this data

StockData. (2026). BeOne Medicines BRUKINSA — China Net Product Revenue ($M) ($M), annual FY2021–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_brukinsa_cn

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.